Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors, which often reside in highly immunosuppressive tumor microenvironments (TMEs). TMEs can be highly abundant in vascular endothelial growth factor A (VEGF), which contributes to immunosuppression and abnormal tumor vasculature. Here, we found that CAR T cells engineered to secrete an anti-VEGF single-chain variable fragment (CAR-αVEGF T cells) achieved superior antitumor efficacy against multiple in vivo models of ovarian cancer and glioma, outperforming conventional CAR T cells with and without combination anti-VEGF antibody therapy. Microscopy, flow cytometry, and transcriptomic analyses revealed that armoring the CAR T cells with anti-VEGF single-chain variable fragments enhanced their activation and mitochondrial fitness and enriched immune-stimulatory signatures among endogenous immune cells in the tumor-bearing brain. Moreover, CAR-αVEGF T cells circumvented multiple detrimental effects associated with on-target CAR T cell therapy, including infiltration of suppressive myeloid cells, exaggerated vasculature abnormalities, and hypoxia. Together, our results provide rationale for the clinical translation of CAR-αVEGF T cells as a safe and potent therapy for solid tumors characterized by elevated VEGF.
Funding Information
  • National Science Foundation (DGE-2034835)
  • National Institutes of Health (2T32CA009120-46A1, 5T32CA009120-45, 5T32CA009120-44)
  • National Institutes of Health (NIGMS T32 GM008042; NIGMS T32 GM152342)
  • Cancer Research Institute (Lloyd J. Old STAR Award)
  • University of California Los Angeles (Whitcome Fellowship)
  • Jean and Stephen Kaplan (N/A)
  • Department of Veteran Affairs (I01BX006019)
  • Department of Veteran Affairs (I01BX006411)

This publication has 74 references indexed in Scilit: